FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/759,125

Filing Date January 20, 2004

First Named Inventor Per Antonsson et al.

Examiner Name Unassigned

Attorney Docket Number 003301-106

Sheet \$1 of

Substitute for form 1449A/PTO & 1449B/PTO

MAY 2 6 2004 3

Vc at			U.S. PATENT DOCUMENTS	NTS		
Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)		
AS	6,420,160		Bloch	07-2002		
AJ	6,066,324		Gissmann et al.	05-2000		
14)	6,361,778		Gissmann et al.	03-2002		

FOREIGN PATENT DOCUMENTS									
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Trans Yes	ation No			
A)	97/46693	(PCT	12/1997		140			
4	99/15630	A1	PCT	04/1999	1				
m	99/48518	A1	PCT	09/1999					
14)	96/11272	A1	PCT	04/1996					
AS	96/33737		PCT	10/1996	†				
1.5			 		<u> </u>				

NON-PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
A	Harald Zur Hausen, "Viruses in Human Cancers, Science 22 November 1991; Vol. 254: Pages 1167 to 1173., Amer. Assn. For the Advancement of Science, Washington, D.C., U.S.A.					
	Douglas R. Lowry et al., "Papillomaviruses and Cervical Cancer: Pathogenesis and Veccine Development", Journal of the National Cancer Institute Monographs No. 23, 1998, Pages 27 to 30, Oxford University Press, Oxford, U.K.					
	Wendy I. White et al., "In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16", Journal of Virology, Feb. 1998, Vol. 72, No. 2, Pages 959 to 964, American Society for Microbiology, Washington, D.C.					
	Heather L. Greenstone et al., "Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model", Proc. National Academy of Sciences, USA, February 1998, Vol. 95, Pages 1800 to 1805., National Academy of Sciences, Washington, D.C., U.S.A.					
	Shiwen Peng et al., "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class I Pathway", Virology, 1998, 240: Pages 147 to 157.					
	Martin Müller et al., "Chimeric Papillomavirus-like Particles", Virology, 1997, 234: Pages 93 to 111, Academic Press, New York, U.S.A.					
	Wendy I. White et al., "Characterization of a Major Neutralizing Epitope on Human Papillomavirus Type 16 L1", Journal of Virology, June 1999, Vol. 73, No. 6, Pages 4882 to 4889, American Society for Microbiology, Washington, D.C.					
	Zhaohui Wang et al., "A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera", Journal of General Virology, 1997, 78: Pages 2209 to 2215, Society for General Microbiology, London, England					
	Marjory SPRAYCAR et al., Eds., Definition of "Derivative", Stedman's Medical Dictionary, 26th Edition, 1995, pgs. 461-462, Williams & Wilkins, Baltimore, Maryland, USA					
	Neil D. CHRISTENSEN et al., "Assembled Baculovirus-Expressed Human Papillomavirus Type 11 L1 Capsid Protein virus-Like Particles are Recognized by Neutralizing Monoclonal Antibodies and Induce High Titres of Neutralizing Antibodies", Journal of General Virology, 1994, pgs. 2271-2276, Vol. 75, Society for General Microbiology, London, ENGLAND					
	John D. NIELAND et al., "Chimeric Pepillomavirus Virus-Like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response", Journal of Cellular Biochemistry, 1999, pgs. 145-152, Vol. 73, Wiley-Liss, New York, New York, USA					
$\sqrt{}$	Hines JF et al., "The Express L1 Proteins of HPV-1, HPV-6, and HPV-11 Distype-specific Epitopes With Native Conformation and Reactivity and Nonneutralizing Antibodies, "Pathobiology, Vol. 64, No. 4, pp. 165-77 (1994), S. Karger A.G., Basel, Switzerland					

Examiner A = %	Date	2 1 1 1 2 1 1
	200	1 4/1/10/4
Signature /// /	Considered	0110707
*EVAMINED: Initial if reference considered whether and their at the		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.